Write a paragraph for an article about the therapeutic approaches used in SLE

In patients with systemic lupus erythematosus (SLE) who present with alopecia, therapeutic approaches mainly align with those used in SLE patients without alopecia, focusing on controlling systemic disease activity and associated immune dysregulation. The cornerstone treatments include corticosteroids, antimalarials such as hydroxychloroquine, and immunosuppressive agents, which are used alone or in combination to manage SLE manifestations including mucocutaneous involvement like alopecia NHS Lupus,SmPC Benlysta.

Studies show that alopecia in SLE often accompanies mucocutaneous disease activity which can be controlled with these immunomodulatory therapies SmPC Benlysta. In terms of drug frequency, although direct comparative data specifically detailing treatment differences between SLE patients with and without alopecia are scarce, literature indicates that among patients with SLE and alopecia-related cutaneous manifestations, immunosuppressants and glucocorticoids remain commonly prescribed at similar rates to those without alopecia Zeng et al. 2025.

In practice, patients with alopecia associated with discoid lupus erythematosus (DLE), a chronic scarring alopecia subtype often overlapping with SLE, may require more intensive local and systemic treatment given the risk of permanent hair loss; such treatments may include topical corticosteroids, antimalarials, and systemic immunosuppressants similar to those used in SLE, underscoring the need for multidisciplinary management Sanz-Cabanillas et al. 2026,Childs and Merola JF. 2025.

In addition, recent evidence suggests patients with SLE and alopecia may have higher prevalence of mucosal ulcers and elevated immunoglobulin levels (IgA and IgG), which correlate with immune activity and may influence therapeutic intensity, although corticosteroid and immunosuppressant dosages appear not to differ significantly between those with and without alopecia Zeng et al. 2025.

Altogether, therapeutic approaches do not fundamentally differ between SLE patients with alopecia and those without; however, the presence of alopecia, particularly with discoid features, may prompt earlier or more aggressive use of immunomodulatory treatments to prevent irreversible hair loss, consistent with managing mucocutaneous lupus manifestations NHS Lupus,Sanz-Cabanillas et al. 2026,Childs and Merola JF. 2025. Further targeted research is needed to clarify if treatment frequencies vary significantly across these patient groups.